CoChat

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

Open access
Hiatt, Andrew, Bohorova, Natasha, Bohorov, Ognian, Goodman, Charles, Kim, Do, Pauly, Michael H., Velasco, Jesus, Whaley, Kevin J., Piedra, Pedro A., Gilbert, Brian E., Zeitlin, Larry · 2014 · Proceedings of the National Academy of Sciences
Cited by 119

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Significance: Recently developed plant hosts that have been genetically engineered to produce mammalian glycosylation enzymes are capable of producing mAbs with specific glycans that satisfy effector function or homogeneity requirements. When produced in this type of plant system, an antirespiratory syncytial virus mAb containing nearly homogeneous glycans with N-acetylglucosamine termini was found to significantly enhance the effectiveness of the approved antibody drug palivizumab. The improvement was because of augmented effector function via binding to antibody Fc receptors, suggesting that classic viral neutralization plays a secondary role in the in vivo function of this antibody. We conclude that enhanced antibody-dependent cell-mediated cytotoxicity activity can be a potent contributor to the in vivo efficacy of palivizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1402458111

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 119

Metadata

Authors
Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., & Zeitlin, L.
Venue
Proceedings of the National Academy of Sciences
Published
2014-04-07
Volume
111
Issue
16
Pages
5992-5997
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2001683849
Cited by
119
References
4
FWCI
8.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. https://app.cochat.ai/papers/10.1073/pnas.1402458111
The paper
Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., & Zeitlin, L. (2014). Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1402458111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.